{"doi":"10.1101/2022.06.10.495677","title":"The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice","abstract":"SUMMARY COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, specific CCP characteristics that promote SARS-CoV-2 control in recipients are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing and high Fc-effector activity, in contrast to those with poor Fc-function, afford effective prophylaxis and therapy in K18-hACE2 mice lethally challenged with SARS-CoV-2-nLuc. Macrophages and neutrophils significantly contributed to CCP effects during therapy but to a reduced extent under prophylaxis. Both IgG and Ig(M+A) were required during therapy, but the IgG fraction alone was sufficient during prophylaxis. Finally, despite neutralizing poorly, SARS-CoV-2 Wuhan-elicited CCPs delayed Delta and Beta variants of concern (VOC)-induced mortality in mice illustrating the contribution of polyclonal Fc-effector functions in immunity against VOCs. Thus, in addition to neutralization, Fc-effector activity is a significant criterion for CCP selection for therapeutic applications.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2022,"id":297132,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9592,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":241565,"name":"Guillaume Beaudoin-Bussières","orcid":"0000-0002-8092-4101","position":1,"is_corresponding":false},{"id":621583,"name":"Kelly Symmes","orcid":"0000-0002-4442-8442","position":2,"is_corresponding":false},{"id":871595,"name":"Marc Cloutier","orcid":"0000-0002-0598-8754","position":3,"is_corresponding":false},{"id":872143,"name":"Éric Ducas","orcid":null,"position":4,"is_corresponding":false},{"id":621585,"name":"Alexandra Tauzin","orcid":"0000-0001-9153-3600","position":5,"is_corresponding":false},{"id":241568,"name":"Annemarie Laumaea","orcid":"0000-0002-4934-597X","position":6,"is_corresponding":false},{"id":624154,"name":"Philippe Bégin","orcid":"0000-0002-9089-4604","position":7,"is_corresponding":false},{"id":241931,"name":"Walther Mothes","orcid":"0000-0002-3367-7240","position":8,"is_corresponding":false},{"id":505003,"name":"Priti Kumar","orcid":"0000-0002-6901-5601","position":9,"is_corresponding":false},{"id":241586,"name":"Renée Bazin","orcid":"0000-0001-9594-2532","position":10,"is_corresponding":false},{"id":241588,"name":"Andrés Finzi","orcid":"0000-0002-4992-5288","position":11,"is_corresponding":false},{"id":241924,"name":"Pradeep D. Uchil","orcid":"0000-0002-7236-858X","position":12,"is_corresponding":false},{"id":621581,"name":"Irfan Ullah","orcid":"0000-0002-7760-8693","position":0,"is_corresponding":true}],"reference_count":54,"raw_metadata":null,"created_at":"2026-07-19T00:31:21.257700Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}